Lars Nootbaar activated by Cardinals from 60-day IL ahead of Reds series opener

What happened

Lars Nootbaar has been reinstated from the 60-day injured list, per MLB Trade Rumors, with the Cardinals optioning Moses Saggese to clear the active roster spot. Manager Oli Marmol told reporters — including Jeff Jones of The Belleville News-Democrat — that the club planned to activate Nootbaar for Friday's series opener against the Reds, and the move was reportedly completed on June 5.

The activation marks Nootbaar's season debut after an absence of more than two months. He reportedly underwent surgery last October to shave down bones on both heels, a procedure that kept him off the field through the early portion of 2026 and required a gradual minor-league rehab process before the Cardinals felt comfortable bringing him back to the big-league roster.

Why it matters

Nootbaar's return gives St. Louis an outfielder who, at his best, has been one of the more complete players on the roster. The timing of the roster construction was smoothed by a pre-existing opening: the Cardinals had already created a 40-man vacancy by returning Rule 5 pick Matt Pushard to the Marlins, which meant the Saggese option handled the active roster math without requiring a more disruptive move.

The 60-day IL is worth understanding in this context. Placement there removes a player from the 40-man roster count entirely, so when Nootbaar was ready to return, the club needed to restore both his 40-man spot and his active roster spot. The Pushard return addressed the former; the Saggese option addressed the latter. It is the kind of quiet roster choreography that tends to go unnoticed until you try to follow along at home.

The numbers

Nootbaar's most recent big-league season, per MLB Trade Rumors, was a difficult one. He posted a career-worst .234/.325/.361 slash line over 583 plate appearances, and the report notes that the heel injuries appeared to be a factor in that performance. His 13 home runs were in a similar range to totals he had posted in fewer plate appearances in prior seasons — a detail that underscores how much the injuries may have cost him in terms of overall production rather than just games missed.

Before returning to the majors, Nootbaar appeared in 11 minor-league rehab games, hitting .233 with a pair of home runs while working his way up to Triple-A Memphis. The rehab line is modest, but the purpose of a rehab assignment is to rebuild timing and test physical readiness rather than to produce a stat line worth framing. He arrived at the big-league level having cleared that bar, at least in the Cardinals' estimation.

Where the club stands

St. Louis enters this weekend series against Cincinnati at 77-85 (.475), sitting fourth in the NL Central, 26 games back in the division. The club has also dropped four straight heading into the series. The Cardinals are eliminated from both the division race and the Wild Card race, where they rank seventh at 11.0 relative to the cut line.

That context shifts what Nootbaar's return means operationally. When postseason baseball is no longer in the picture, a season's remaining games become something closer to an extended audition — for the roster, for the coaching staff's read on personnel, and for players returning from injury who need to prove that last year's numbers were the heels talking, not the player. Getting a sustained look at Nootbaar healthy answers questions that an injury-affected prior campaign left conspicuously open.

The Cardinals host Cincinnati for three games at Busch Stadium this weekend. Friday's opener features Kyle Leahy against Brady Singer. Saturday has Matthew Liberatore opposing Nick Lodolo. Sunday sends Michael McGreevy to the mound against Rhett Lowder.

Is Nootbaar in the lineup Friday?

Per MLB Trade Rumors, Marmol indicated Nootbaar would be activated specifically for Friday's series opener against Cincinnati, and the reinstatement was reportedly completed on June 5 — the same date as that game. Whether he steps into the starting lineup immediately, bats in a particular spot, or is eased back in some other fashion was not detailed in the reporting.

What we don't know yet

The report does not specify how the Cardinals plan to deploy Nootbaar in the near term — whether he moves into an everyday role from the start or is managed carefully given the nature of his surgery and the length of his absence. Heel procedures can carry long recovery arcs, and the club's approach to his workload in the early weeks is an open question the reporting does not resolve.

How Saggese fits back into the picture is similarly unaddressed. MLB Trade Rumors does not detail what the option means for his development timeline or when he might next factor into the active roster. Options are a finite resource under general league rules, and how clubs manage them across a season carries downstream consequences — but the specifics of Saggese's situation were not reported here.

The Cardinals' broader roster construction for the remainder of the season, particularly as they play out a year in which postseason baseball is no longer a factor, also remains to be seen. Nootbaar's return is one piece of that picture, not the whole frame.

What to watch

The most immediate thing to monitor is simply how Nootbaar looks and feels over the first few weeks back. A .233 rehab line and a surgically repaired pair of heels are not the most reassuring combination of inputs heading into a big-league series, but the Cardinals reportedly believe he is ready enough to activate. Whether the career-worst slash line from his most recent big-league season reflected the player or the heels will be one of the more interesting questions this roster has to offer down the stretch.

Saggese's path back to the active roster, and how the Cardinals manage their outfield depth as the season continues, is worth tracking alongside Nootbaar's workload. And with a four-game losing streak in tow and a Reds team coming to Busch Stadium, the next few days will at least give Nootbaar a live look at what he has been missing since last October.